Article Text

PDF
Changing frequency of equivocal HER-2/neu scores and factors predictive of negative HER 2/neu fluorescent in situ hybridisation in invasive carcinomas of the breast
  1. Fouad Boulos1,
  2. Chantal G Farra1,
  3. Ehab M Saad Aldin2,3,
  4. Cleo Masaad1,
  5. Yasmin Hassoun2,
  6. Faysal Fedda1,4,
  7. Hassan Doumiati2,
  8. Ayman N Tawil1,
  9. Zeina Nasser2,
  10. Zeina Nahleh5,
  11. Arafat Tfayli2
  1. 1Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon
  2. 2Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
  3. 3Department of Internal Medicine, Medstar Good Samaritan Hospital Affiliated with the Johns Hopkins University, Baltimore, Maryland, USA
  4. 4Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
  5. 5Department of Internal Medicine, Texas Tech University, El Paso, Texas, USA
  1. Correspondence to Dr Arafat Tfayli, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; at35{at}aub.edu.lb

Abstract

Background Analysis of human epidermal growth factor receptor 2 (HER-2) status has become standard of care in breast cancer patients due to its important prognostic and therapeutic implications. Immunohistochemistry (IHC) is the most commonly used primary method for detection of HER-2 overexpression. Controversy exists on the interpretation of samples that are equivocal for HER 2 status (IHC 2+). Recent guidelines state that samples equivocal for HER 2 status require validation with fluorescent in situ hybridisation (FISH). The use of FISH, however, despite higher accuracy comes at a higher cost that is not affordable to all patients.

Methods This study is a retrospective study conducted at the American University of Beirut Medical Center, including women diagnosed with breast cancer with equivocal IHC scores presenting between 2009 and 2011. We attempted to correlate clinicopathological characteristics of patients diagnosed with breast cancer that can influence conclusions made on HER 2 status when analysing IHC equivocal samples in an effort to decrease the need for FISH testing. 113 patients in our records were included; charts were reviewed for different patient clinical characteristics and samples were analysed for pathological characteristics.

Results Using logistic regression, progesterone receptor status and HER-2 staining of the normal glands around the tumour by IHC were the two statistically significant variables that showed association with FISH results. The strength of progesterone receptor status positivity and HER-2 staining of the normal glands around the tumour were proportional to the likelihood of a negative FISH. Also, the presence of strong and diffuse hormone receptor positivity in low-grade tumours was predictive of negative HER-2 status.

Conclusions In countries where resources are strained, oncologists need to think of measures to minimise the increasing financial burden of cancer care. Our study serves to highlight a few clinicopathological characteristics that might eliminate the need for further testing through FISH.

  • BREAST
  • IMMUNOHISTOCHEMISTRY
  • FISH
  • CANCER

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.